{"id":"cycloguanil","rwe":[{"pmid":"41643235","year":"2026","title":"Drug repurposing strategy to identify the putative leads against the Epidermal growth factor receptor (EGFR) from the USFDA-approved drug pool: Investigating the utility as an anticancer agent.","finding":"","journal":"Journal of molecular graphics & modelling","studyType":"Clinical Study"},{"pmid":"41418346","year":"2026","title":"Mechanisms of NMDA receptor inhibition by chlorhexidine and alexidine.","finding":"","journal":"Biochemical and biophysical research communications","studyType":"Clinical Study"},{"pmid":"41322301","year":"2025","title":"Ex vivo perfusion model of mouse liver and its application to analyze the effects of OCT1 deficiency.","finding":"","journal":"Frontiers in pharmacology","studyType":"Clinical Study"},{"pmid":"41241020","year":"2026","title":"The impact of acacetin on proguanil metabolism: An in vitro and in vivo study.","finding":"","journal":"Biochemical pharmacology","studyType":"Clinical Study"},{"pmid":"40839929","year":"2025","title":"Integrated computational strategies for the identification of Plasmodium falciparum dihydrofolate reductase inhibitors.","finding":"","journal":"Computers in biology and medicine","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Dihydrofolate reductase","category":"target"},{"label":"DHFR","category":"gene"},{"label":"P01BB02","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antimalarials","category":"pharmacology"},{"label":"Antiparasitic Agents","category":"pharmacology"},{"label":"Antiprotozoal Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Folic Acid Antagonists","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["cycloguanil","cycloguanil embonate","cycloguanil pamoate"],"offLabel":[],"synonyms":["cycloguanil","cycloguanil embonate","cycloguanil pamoate"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"target":"Dihydrofolate reductase, Bifunctional dihydrofolate reductase-thymidylate synthase, Dihydrofolate reductase","targets":[{"gene":"DHFR","source":"DrugCentral","target":"Dihydrofolate reductase","protein":"Dihydrofolate reductase"}],"modality":"Small Molecule","explanation":"Think of DNA like a blueprint for your body. Dihydrofolate reductase is an enzyme that helps build this blueprint. Cycloguanil stops this enzyme from working, which can help prevent the growth and replication of certain cells, like the parasites that cause malaria.","oneSentence":"Cycloguanil works by blocking the enzyme dihydrofolate reductase, which is necessary for DNA synthesis in certain cells.","technicalDetail":"Cycloguanil is a competitive inhibitor of dihydrofolate reductase, binding to the enzyme's active site and preventing the conversion of dihydrofolate to tetrahydrofolate, which is essential for DNA synthesis and cell division."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/754","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CYCLOGUANIL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:21:49.996985","biosimilars":[],"competitors":[{"drugName":"proguanil","drugSlug":"proguanil","fdaApproval":"2000-07-14","relationship":"same-class"},{"drugName":"atovaquone","drugSlug":"atovaquone","fdaApproval":"1992-11-25","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"chloroquine","drugSlug":"chloroquine","fdaApproval":"1949-10-31","patentStatus":"Unknown","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"cycloguanil","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"proguanil","brandName":"proguanil","genericName":"proguanil","approvalYear":"2000","relationship":"same-class"},{"drugId":"atovaquone","brandName":"atovaquone","genericName":"atovaquone","approvalYear":"1992","relationship":"same-class"},{"drugId":"chloroquine","brandName":"chloroquine","genericName":"chloroquine","approvalYear":"1949","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"002945","UNII":"26RM326WVN","CHEBI":"CHEBI:4003","INN_ID":"1527","UMLSCUI":"C0056751","ChEMBL_ID":"CHEMBL747","KEGG_DRUG":"D02387","DRUGBANK_ID":"DB14763","PDB_CHEM_ID":" 1CY","PUBCHEM_CID":"9049","SNOMEDCT_US":"28223003","IUPHAR_LIGAND_ID":"10027","SECONDARY_CAS_RN":"609-78-9","MESH_SUPPLEMENTAL_RECORD_UI":"C026009"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":364,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"P01BB02","allCodes":["P01BB02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 May","pmid":"41643235","title":"Drug repurposing strategy to identify the putative leads against the Epidermal growth factor receptor (EGFR) from the USFDA-approved drug pool: Investigating the utility as an anticancer agent.","journal":"Journal of molecular graphics & modelling"},{"date":"2026 Jan 18","pmid":"41418346","title":"Mechanisms of NMDA receptor inhibition by chlorhexidine and alexidine.","journal":"Biochemical and biophysical research communications"},{"date":"2025","pmid":"41322301","title":"Ex vivo perfusion model of mouse liver and its application to analyze the effects of OCT1 deficiency.","journal":"Frontiers in pharmacology"},{"date":"2026 Jan","pmid":"41241020","title":"The impact of acacetin on proguanil metabolism: An in vitro and in vivo study.","journal":"Biochemical pharmacology"},{"date":"2025 Sep","pmid":"40839929","title":"Integrated computational strategies for the identification of Plasmodium falciparum dihydrofolate reductase inhibitors.","journal":"Computers in biology and medicine"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"CYCLOGUANIL","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cycloguanil is a small molecule drug that targets dihydrofolate reductase, an enzyme involved in DNA synthesis. It is not clear if it is FDA approved or commercially available, and its patent status is unknown. Cycloguanil works by inhibiting the enzyme, which is necessary for the growth and replication of certain cells. It is used to treat malaria, but its exact indications and commercial status are unclear. Further research is needed to determine its safety and efficacy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}